bioRxiv · 10.1101/2020.05.13.093088
Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody
Abstract
Effective therapies are urgently needed for the SARS-CoV-2/COVID19 pandemic. We identified panels of fully human monoclonal antibodies (mAbs) from eight large phage-displayed Fab, scFv and VH libraries by panning against the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. One high affinity mAb, IgG1 ab1, specifically neutralized replication competent SARS-CoV-2 with exceptional potency as measured by two different assays. There was no enhancement of pseudovirus infection in cells expressing Fc{gamma} receptors at any concentration. It competed with human angiotensin-converting enzyme 2 (hACE2) for binding to RBD suggesting a competitive mechanism of virus neutralization. IgG1 ab1 potently neutralized mouse ACE2 adapted SARS-CoV-2 in wild type BALB/c mice and native virus in hACE2 expressing transgenic mice. The ab1 sequence has relatively low number of somatic mutations indicating that ab1-like antibodies could be quickly elicited during natural SARS-CoV-2 infection or by RBD-based vaccines. IgG1 ab1 does not have developability liabilities, and thus has potential for therapy and prophylaxis of SARS-CoV-2 infections. The rapid identification (within 6 days) of potent mAbs shows the value of large antibody libraries for response to public health threats from emerging microbes.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Li, W., Drelich, A., Martinez, D. R., Gralinski, L. E., Chen, C., Sun, Z., Liu, X., Zhelev, D. V., Zhang, L., Peterson, E. L., Conard, A., Mellors, J. W., Tseng, C.-T., Baric, R. S., Dimitrov, D. S.. 2020-05-14. Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody. https://doi.org/10.1101/2020.05.13.093088
Cite the original work for its findings. Save a collection to share your selection of sources.